Epidemiology and pharmacotherapy of lower respiratory tract infections: role of inhibitor-protected aminopenicillins
https://doi.org/10.21518/2079-701X-2018-15-76-81
Abstract
The article is devoted to the role of inhibitor-protected aminopenicillins in the treatment of community-acquired infections of the lower respiratory tract. Data are provided on the relevance of LRTIs, the aetiology of CAP and infectious exacerbations of COPD, the pharmacological characteristics of amoxicillin /clavulanate, which allowed it to occupy a leading role in the antibiotic therapy regimens of these diseases. The paper presented modern ideas about the directions of antimicrobial therapy of CAP and its complications (lung abscess, pleural empyema). It considered the antibacterial therapy indications for exacerbations of chronic bronchitis /COPD, and presented the treatment regimens with due account for the current clinical guidelines.
About the Author
A. A. Zaitsev
Burdenko Main Military Clinical Hospital of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
Moscow
References
1. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
2. Zaitsev AA, Klochkov OI, Sinopalnikov AI. Treatment of community-acquired pneumonia in military personnel in hospital environment (pharmacoeconomic analysis). Klinitsist, 2007, 4: 22-28
3. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbation of chronic bronchitis. Clin Ther, 1999, 21: 576-591.
4. Anzueto A. Acute exacerbation of chronic bronchitis. J Crit Illness, 1999, 14(Suppl): S27-S33.
5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on the Management of CommunityAcquired pneumonia in Adults. Clin Infect Dis, 2007, 44: S27-72.
6. Clinical guidelines for the d iagnosis and treatment of community-acquired pneumonia in adults. Project, 2018. Available at: http://www.antibiotic.ru/index.php?article=2775.
7. Ovchinnikov YuV, Zaitsev AA, Sinopalnikov AI, Kryukov EV, Kharitonov MYu, Chernov SA, Makarevich AM. Community-acquired pneumonia in military personnel: strategies for management and antimicrobial therapy. Voenno-Meditsinskiy Zhurnal, 2016, 337 (3): 4-14.
8. Kuchmin AN, Akimkin VG, Sinopalnikov AI, Zaytsev AA, Zhogolev SD, Cherkashin DV. Diagnosis, treatment and prevention of community-acquired pneumonia in the military personnel of the Ministry of Defense of the Russian Federation. Methodical instructions. Moscow, 2010.
9. Sinopalnikov AI, Zaitsev AA. Clinical efficacy and safety of step-down monotherapy with azithromycin in patients with communityacquired pneumonia in the hospital environment. Pharmateca, 2006, 16: 11.
10. Отчет по проекту ЦЕРБЕРУС. Смоленск: НИИАХ, 2014. /Report on the CERBERUS project. Smolensk: NIIAH, 2014
11. Biedenbach D, Badal R, Huang M, et al. In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with CommunityAcquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study. Infect Dis Ther, 2016, 5(3): 405.
12. Ferech M, Coenen S, Dvorakova K, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother, 2006, 58(2): 408-12.
13. Zaitsev AA, Chudnova EV, Klochkov OI. Antibacterial therapy of community-acquired pneumonia in the military medical institutions. VoennoMeditsinskiy Zhurnal, 2007, 328 (8): 29-35.
14. Rachina SA, Zaitsev AA. Pharmacoepidemiological studies of antibacterial drugs for community-acquired respiratory infections. A guide for practitioners “Community-acquired respiratory tract infections: diagnosis and treatment.” M., 2008: 254-271.
15. Zaitsev AA, Kolobanova EV, Sinopalnikov AI. Community-acquired respiratory tract infections: a role of inhibitor-protected aminopenicillins. Lechashchiy Vrach, 2008, 5: 75-79.
16. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature, 1940, 373: 837.
17. Zaitsev AA, Sinopalnikov AI. Inhibitor-protected aminopenicillins: the Renaissance era of beta-lactams. RMJ, 2007, 15:24
18. Neu HC, Wilson, APR. Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother, 1993, 5: 67–93.
19. Berkovitch M, Diav-Citrin O, Greenberg R. Et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol, 2004, 58(3): 298-302.
20. Sinopalnikov, AI, Zaitsev AA. Compliance of patients with respiratory tract infections. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2008, 10 (1): 50-59.
21. Zaitsev AA, Schegolev AV. Diagnosis and treatment of severe influenza A (H1N1/09) virus-induced lung injury: practical guidelines. Voenno-Meditsinskiy Zhurnal, 2016, 337 (3): 39-46.
22. Tenitsky AF, Skipin MV, Zaitsev AA. Communityacquired pneumonia in individuals with an increased risk of disease. Voenno-Meditsinskiy Zhurnal, 2004, 6: 61.
23. Zaitsev AA, Mironov MB, Makarevic AV, Sinopalnikov AI. Lung abscess. Lechashchiy Vrach, 2008, 8: 14-18.
24. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987, 106: 196–204.
25. Zaitsev AA, Ovchinnikov YuV, Kondratieva TV. Biological inflammatory markers in community-acquired pneumonia. Consilium Medicum, 2014, 16 (11): 36-41.
26. Sinopalnikov AI, Zaitsev AA. Modern views of the pharmacotherapy of exacerbations of chronic obstructive pulmonary disease. Lechashchiy Vrach, 2009, 10: 45-49.
Review
For citations:
Zaitsev AA. Epidemiology and pharmacotherapy of lower respiratory tract infections: role of inhibitor-protected aminopenicillins. Meditsinskiy sovet = Medical Council. 2018;(15):76-81. (In Russ.) https://doi.org/10.21518/2079-701X-2018-15-76-81
Views:
854
Email this article 